A

Arthritis & Rheumatic Disease Specialties | Aventura, FL

Research site
(Unclaimed)
Location
2801 North East 213th Street Suite 801, Aventura, Florida, United States of America
Site insights

Top conditions

Arthritis (11 trials)

Rheumatoid Arthritis (8 trials)

Systemic Lupus Erythematosus (7 trials)

Psoriatic Arthritis (4 trials)

Gout (3 trials)

Top treatments

Upadacitinib
ABT-494
BIIB059
Litifilimab
ABBV-599
Leronlimab
Macitentan
GLPG3667
BMS-986165
Adalimumab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

12 of 26
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1)

The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active pso...

Active, not recruiting
Psoriatic Arthritis
Biological: Risankizumab
Biological: Placebo

The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (Ps...

Active, not recruiting
Psoriatic Arthritis (PsA)
Biological: Risankizumab
Biological: Placebo

The study objectives of Period 1 are to compare the efficacy, safety, and tolerability of upadacitinib 15 mg once daily (QD) and 30 mg QD versus plac...

Active, not recruiting
Psoriatic Arthritis
Drug: Placebo
Drug: Upadacitinib

A study evaluating the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GLPG3667 administered orally once daily fo...

Enrolling
Systemic Lupus Erythematosus
Drug: GLPG3667
Drug: Placebo

This protocol includes 2 standalone studies with randomization, data collection, analysis and reporting conducted independently.The main objectives o...

Active, not recruiting
Spondyloarthritis
Drug: Placebo
Drug: Upadacitinib

The primary objective of this study is to evaluate the long-term safety and tolerability of litifilimab in participants with active systemic lupus er...

Invitation-only
Systemic Lupus Erythematosus (SLE)
Drug: Litifilimab-matching placebo
Drug: Litifilimab

The primary objective of this study is to demonstrate efficacy of litifilimab (BIIB059) compared with placebo in participants with active systemic lu...

Enrolling
Lupus Erythematosus, Systemic
Drug: Litifilimab
Drug: Placebo

The main objective of the trial is to characterize the long-term safety and tolerability of BMS-986165 in subjects with Systemic Lupus Erythematosus...

Active, not recruiting
Systemic Lupus Erythematosus
Drug: BMS-986165

Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how s...

Enrolling
Systemic Lupus Erythematosus
Drug: Upadacitinib
Drug: Placebo

Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will assess how...

Enrolling
Rheumatoid Arthritis
Drug: Adalimumab
Drug: Upadacitinib

The aim of this 12-month randomized multi-regional double-blind parallel group allopurinol and placebo-controlled phase 3 study is to assess the effi...

Enrolling
Hyperuricemia
Tophi
Drug: Tigulixostat
Drug: Placebo

The RESET-RA study will assess the safety and efficacy of the SetPoint System (study device) for the treatment of adult patients with active, moderat...

Active, not recruiting
Rheumatoid Arthritis
Procedure: Implant Procedure
Drug: Conventional Synthetic DMARD

Trial sponsors

AbbVie logo

AbbVie (10 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems